|国家预印本平台
首页|聚右旋乳酸-胸腺五肽立体复合物的药物缓释研究

聚右旋乳酸-胸腺五肽立体复合物的药物缓释研究

Novel stereocomplex formed by poly(D-lactide) and thymopentin for controlled drug delivery

中文摘要英文摘要

胸腺五肽(TP5)作为一种典型的左旋多肽类药物,可以与右旋聚乳酸(PDLA)形成立体复合产物。通过简单的混合PDLA的乙腈溶液与TP5的水溶液,可以得到可作为药物释放体系的立体复合物,并用FT-IR和DSC证明了复合物的形成,同时研究了PDLA的分子量及其立体复合物组成等参数对药物释放行为的影响。实验中样品的药物释放曲线呈现出了近似于零级释放曲线的特征。对释放行为的研究表明,较高分子量的聚合物呈现较的低药物释放速率,这是因为紧密的结构影响了立体复合物的降解和药物扩散。胸腺五肽的水溶性很好,载药量在一定范围对于药物释放的影响不大。但是载药量过大会导致突释现象。在所研究的样品中,接近35%的药物胸腺五肽在200个小时内可以被成功释放,且在200小时时药物缓释行为仍然没有停止。

Poly(D-lacitde)(PDLA) were synthesized by ring opening polymerization of D-lactide using zinc lactate as catalyst. Stereocomplexes of PDLA/TP5 were obtained by mixing solutions of acetonitrile containing PDLA and aqueous solutions of thymopentin (TP5) through stereocomplexation between PDLA and TP5 chains which were proved by FT-IR and DSC. Thymopentin was uesd as a model drug to evaluate the potential of PDLA for forming drug delivery systems with L-con?gured peptides. The in?uence of PDLA molecular weight and the stereocomplex composition on the release behavior were investigated. Release of TP5 performed as zero-order release kinetics. Higher polymer molecuar leads to slower release rate due to more compact structure which disfavors degradation of stereocomplexes and drug diffusion. Drug load exhibits little in?uence on the release pro?le due to the high water solubility of TP5 while too much drug load will lead to a brust release. In all cases, nearly 35% of TP5 is released in 200 hours and there was no sign of an ending of this controlled release behavior at that time.

韦嘉、范仲勇、张彦、李速明

药学生物化学高分子化合物工业

立体复合物聚乳酸胸腺五肽药物缓释

stereocomplexpoly(lactide)thymopentincontrolled drug delivery

韦嘉,范仲勇,张彦,李速明.聚右旋乳酸-胸腺五肽立体复合物的药物缓释研究[EB/OL].(2011-04-26)[2025-07-22].http://www.paper.edu.cn/releasepaper/content/201104-676.点此复制

评论